FranΓ§aisπ See the interactive version (live chart) β
For Inspire Medical Systems, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 29% were profitable, average return +4% (112 calls). At 3 months: +0% average return (40% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Piper Sandler | 18 | 28% | +10% |
| Truist Securities | 17 | 18% | -14% |
| SVB Leerink | 9 | 44% | +39% |
| Keybanc | 9 | 0% | -41% |
| Wells Fargo | 8 | 75% | +80% |
The analyst consensus on Inspire Medical Systems, Inc. (INSP) is "Hold" (27 bullish, 0 bearish calls over 12 months). This is not advice: historically, 29% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $60.00 (-1% vs $60.82), ranging from $45.00 to $85.00 (11 analysts).
Over 1 year, 29% of analyst targets on Inspire Medical Systems, Inc. were profitable, for an average return of +4% (across 112 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $60.00 within 12 months, i.e. -1% vs the current price. The most bullish targets $85.00, the most cautious $45.00.
Note: analyst targets are 12-month (median $60.00, -1%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (29%), and the stock's past trajectory.
Detailed valuation data for Inspire Medical Systems, Inc. is available in the interactive analysis.
π See the full interactive analysis of Inspire Medical Systems, Inc. β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.